On December 12, the latest announcement on the CDE website showed that the listing application for donafinil toluenesulfonate tablets, a class 1 new drug of Zejing pharmaceutical, was planned to be included in the priority review. The proposed indication of this application is to treat advanced (inoperable or metastatic) hepatocellular carcinoma.<br>
正在翻译中..